Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Stomach Neoplasms 6Neoplasms 3Small Cell Lung Carcinoma 2Recurrence 2Lymphoma 2Non-Erosive Reflux Disease 1Melanoma 1Lymphoma, Mantle-Cell 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Hematologic Neoplasms 1Helicobacter Infections 1Gastrointestinal Hemorrhage 1Gastroesophageal Reflux 1Gastritis, Atrophic 1Dyspepsia 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1COVID-19 1Barrett Esophagus 1Atrophy 1Advanced Solid Tumors 1Advanced Solid Malignancies 1Adenocarcinoma 1Acrocephalosyndactylia 1

Interventions

Cyclophosphamide 447Rituximab 406Etoposide 225Vincristine 217Doxorubicin 204Filgrastim 201Prednisone 178Cytarabine 160Radiotherapy 152fludarabine phosphate 148Methotrexate 137Peripheral Blood Stem Cell Transplantation 130Melphalan 128fludarabine 116Busulfan 101Dexamethasone 93Tacrolimus 76Carmustine 74Granulocyte Colony-Stimulating Factor 73Mycophenolic Acid 72Gemcitabine 66Bortezomib 65Antilymphocyte Serum 65Whole-Body Irradiation 63Bendamustine Hydrochloride 63Lenalidomide 62Cyclosporine 62Ifosfamide 58sargramostim 51Methylprednisolone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma × Rabeprazole × Clear all
NCT05602597 2024-03-06

HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI

Hutchmed

Phase 1 Completed
59 enrolled
Lymphoid

Lymphoma, Recurrence

NCT05571787 2023-02-23

HMPL-523 Food Effect and Proton Pump Inhibitor Study

Hutchmed

Phase 1 Completed
26 enrolled
Lymphoid

Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡